Ijin Joo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ijin Joo has a total of 328 co-authors. Here are the top co-authors by number of shared publications:
- Jeong Min Lee
Department of Radiology, Seoul National University Hospital, Seoul, Korea, Republic of
36 shared publications Sun Kyung Jeon
14 shared publications- Hyo-Jin Kang
Department of Radiology, Seoul National University Hospital, Seoul, Korea
12 shared publications - Jeong Hee Yoon
Department of Radiology, Seoul National University Hospital, Seoul, Korea
12 shared publications - Sang Hyun Choi
Department of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea
10 shared publications - Jeongin Yoo
Department of Radiology, Seoul National University Hospital, Seoul, Korea
9 shared publications
Latest Publications
- 6 November 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
From tissue phenotyping to systemic outcomes — the expanding clinical relevance of quantitative liver MRI
Clinical and Molecular Hepatology
- 6 November 2026
- Published by The Korean Association for the Study of the Liver in Clinical and Molecular Hepatology
From tissue phenotyping to systemic outcomes — the expanding clinical relevance of quantitative liver MRI
Clinical and Molecular Hepatology
- Open Access
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Simplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- 2 November 2026
- Published by Wiley in Journal of Magnetic Resonance Imaging
Open AccessSimplifying CT / MRI LI ‐ RADS v2018 Maintains Diagnostic Performance: An Individual Participant Data Meta‐Analysis
Background: The Liver Imaging Reporting and Data System (LI‐RADS) diagnostic algorithm assesses hepatocellular carcinoma (HCC) probability of liver observations in high‐risk individuals, but complexity may limit its adoption. Purpose: To evaluate whether LI‐RADS v2018 can be simplified without impairing diagnostic performance by removing threshold growth (TG) and reducing size cut‐offs. Study Type: Retrospective meta‐analysis. Population: Eight thousand five hundred eighty‐two patients (mean age: 59 ± 11 years; 6610 male) at risk for HCC with CT/MRI (986 CT, 6554 MRI, and 1042 CT/MRI). Field Strength/Sequence: Field strength: 1.5T and 3.0T; sequences varied by institution per LI‐RADS technical requirements. Assessment: LI‐RADS v2018 using major features only was compared with seven simplifications removing TG and/or applying single size cut‐offs (≥ 10, ≥ 15, and ≥ 20 mm) in individual participant data (IPD) of 64 studies (29 institutions, 11 countries) from the LI‐RADS Living Systematic Review and IPD Meta‐analysis Project. Risk of bias was assessed with QUADAS‐2. Statistical Tests: Summary receiver operating characteristic curves estimated area under the curve (AUC) across LR‐3 to LR‐5; LR‐5 sensitivity, specificity, and positive predictive value (PPV) were estimated using a one‐step bivariate mixed‐effects model. Differences were assessed by cluster bootstrap. p < 0.05 indicated significance, uncorrected for multiple comparisons. Results: Nine thousand four hundred six observations were included. Excluding TG with a 10‐mm cut‐off showed AUC similar to LI‐RADS v2018 (0.80 vs. 0.81, p = 0.44) and significantly higher LR‐5 sensitivity (73.8% vs. 71.8%) with similar specificity (72.5% vs. 73.7%, p = 0.13) and PPV (97.8% vs. 97.8%, p = 0.73). Removing TG with 15‐mm and 20‐mm cut‐offs had significantly lower AUC than v2018 (−0.03 [95% CI: −0.041, −0.019]; −0.043 [−0.054, −0.032], respectively) and sensitivity (−13.2% [95% CI: −14.5%, −12.0%]; −30.1% [−31.7%, −28.5%], respectively). Of the 64 studies, 17 had low‐risk of bias, and 56 had low applicability concerns. Conclusion: Simplifying LI‐RADS v2018 by removing TG and using a 10‐mm size cut‐off preserved diagnostic table AUC while improving LR‐5 sensitivity without loss of specificity or PPV. Protocol Registration: Open Science Framework ( https://osf.io/cjwgp ). Evidence Level: 3. Technical Efficiency: Stage 2.
- Open Access
- 30 September 2026
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 26 (2) , 205-219
Toward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts
The role of liver biopsy in hepatocellular carcinoma (HCC) is being re-evaluated in the era of precision oncology and biomarker-driven systemic therapy. Although histopathological examination remains the diagnostic gold standard, HCC is unique among solid tumors in that accurate non-invasive imaging criteria allow diagnosis without routine biopsy in selected clinical settings. However, increasing biological heterogeneity, expanding therapeutic options, and the growing need for molecular stratification have renewed interest in tissue-based evaluation. Recent international guidelines have gradually broadened the indications for liver biopsy, particularly in selected diagnostic scenarios, prior to systemic therapy, and for molecular profiling. Beyond diagnostic confirmation, liver biopsy provides important information for histological subtyping, prognostic stratification, and biomarker discovery. Advances in immunohistochemistry, next-generation sequencing, and artificial intelligence-assisted pathology have further enhanced the clinical value of tumor tissue. In parallel, contemporary cohort studies indicate that liver biopsy is associated with low complication rates when modern techniques and standardized peri-procedural management are applied. Despite these advances, the integration of liver biopsy into routine clinical practice remains limited. To contextualize this gap, the Korean Liver Cancer Association conducted a nationwide survey of HCC specialists. The survey showed that liver biopsy is infrequently performed in current practice due to perceived procedural risks and limited immediate impact on therapeutic decision-making. Taken together, accumulating evidence supports a reappraisal of the clinical role of liver biopsy in HCC. Optimizing procedural safety, standardizing indications, and integrating tissue-based molecular insights into therapeutic decision-making may help bridge the gap between emerging evidence and real-world practice.
- 30 September 2026
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 26 (2) , 205-219
Open AccessToward a future role for liver biopsy in HCC: literature evidence and survey-based perspectives from Korean experts
The role of liver biopsy in hepatocellular carcinoma (HCC) is being re-evaluated in the era of precision oncology and biomarker-driven systemic therapy. Although histopathological examination remains the diagnostic gold standard, HCC is unique among solid tumors in that accurate non-invasive imaging criteria allow diagnosis without routine biopsy in selected clinical settings. However, increasing biological heterogeneity, expanding therapeutic options, and the growing need for molecular stratification have renewed interest in tissue-based evaluation. Recent international guidelines have gradually broadened the indications for liver biopsy, particularly in selected diagnostic scenarios, prior to systemic therapy, and for molecular profiling. Beyond diagnostic confirmation, liver biopsy provides important information for histological subtyping, prognostic stratification, and biomarker discovery. Advances in immunohistochemistry, next-generation sequencing, and artificial intelligence-assisted pathology have further enhanced the clinical value of tumor tissue. In parallel, contemporary cohort studies indicate that liver biopsy is associated with low complication rates when modern techniques and standardized peri-procedural management are applied. Despite these advances, the integration of liver biopsy into routine clinical practice remains limited. To contextualize this gap, the Korean Liver Cancer Association conducted a nationwide survey of HCC specialists. The survey showed that liver biopsy is infrequently performed in current practice due to perceived procedural risks and limited immediate impact on therapeutic decision-making. Taken together, accumulating evidence supports a reappraisal of the clinical role of liver biopsy in HCC. Optimizing procedural safety, standardizing indications, and integrating tissue-based molecular insights into therapeutic decision-making may help bridge the gap between emerging evidence and real-world practice.
- 14 July 2026
- Published by Elsevier in Clinical Radiology
- Vol. 100
Automated analysis of abdominal body composition using MRI: algorithm development and validation via CT comparison
- 14 July 2026
- Published by Elsevier in Clinical Radiology
- Vol. 100
Automated analysis of abdominal body composition using MRI: algorithm development and validation via CT comparison
- 3 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108939
CT-Based Intratumoral Artery-Like Volume for Pre-Treatment Lung Shunt Estimation in Hepatocellular Carcinoma
- 3 July 2026
- Published by Elsevier in Journal of Vascular and Interventional Radiology
- Vol. 37 (10) , 108939
CT-Based Intratumoral Artery-Like Volume for Pre-Treatment Lung Shunt Estimation in Hepatocellular Carcinoma
- Open Access
- 2 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (4) , 695-711
Advances in the imaging of liver cancer
- 2 July 2026
- Published by Elsevier in Journal of Hepatology
- Vol. 85 (4) , 695-711
Open AccessAdvances in the imaging of liver cancer
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1) , e252803
Noncontrast Abbreviated MRI for Post-TACE Treatment Response Monitoring of Hepatocellular Carcinoma Based on Ancillary Features from LI-RADS
Noncontrast abbreviated MRI demonstrated moderate diagnostic accuracy for post–transarterial chemoembolization treatment response monitoring in patients with hepatocellular carcinoma, including viable tumors in treated lesions and newly developed tumors, but lower accuracy than full-sequence liver MRI.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1) , e252803
Noncontrast Abbreviated MRI for Post-TACE Treatment Response Monitoring of Hepatocellular Carcinoma Based on Ancillary Features from LI-RADS
Noncontrast abbreviated MRI demonstrated moderate diagnostic accuracy for post–transarterial chemoembolization treatment response monitoring in patients with hepatocellular carcinoma, including viable tumors in treated lesions and newly developed tumors, but lower accuracy than full-sequence liver MRI.
- 17 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 113021
CT attenuation–based hepatic steatosis assessment using 3D organ segmentation: Impact of tube voltage and need for cutoff adjustment
- 17 June 2026
- Published by Elsevier in European Journal of Radiology
- Vol. 203, 113021
CT attenuation–based hepatic steatosis assessment using 3D organ segmentation: Impact of tube voltage and need for cutoff adjustment
- Open Access
- 30 September 2025
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 25 (2) , 217-232
Preventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies
Noninvasive imaging-based diagnosis of hepatocellular carcinoma (HCC) in high-risk patients plays a central role in clinical practice. Current major guidelines typically rely on the radiologic hallmark of nonrim arterial phase hyperenhancement followed by nonperipheral washout, criteria designed to achieve both high positive predictive value and sufficient specificity when applied within well-defined target populations. Despite these criteria, false positive diagnoses still occur and can lead to unnecessary or inappropriate treatment, as various benign and non-HCC malignant lesions may exhibit vascular features that overlap with the classic appearance of HCC. Furthermore, treatment decisions are occasionally guided by imaging findings even in patients outside the target population who are being evaluated for possible HCC, in whom vascular patterns are less specific and the risk of false positive diagnosis is inherently higher. Minimizing the risk of false positive diagnosis requires not only adherence to validated imaging criteria but also clinical and contextual integration when findings are uncertain. This includes consideration of ancillary features, tumor markers, and, when appropriate, further evaluation through biopsy, additional imaging, or follow-up. This review outlines a range of HCC mimickers and provides practical strategies to support accurate imaging interpretation and reduce false positive diagnoses in clinical practice.
- 30 September 2025
- Published by Korean Liver Cancer Association in Journal of Liver Cancer
- Vol. 25 (2) , 217-232
Open AccessPreventing false positive imaging diagnosis of HCC: differentiating HCC from mimickers and practical strategies
Noninvasive imaging-based diagnosis of hepatocellular carcinoma (HCC) in high-risk patients plays a central role in clinical practice. Current major guidelines typically rely on the radiologic hallmark of nonrim arterial phase hyperenhancement followed by nonperipheral washout, criteria designed to achieve both high positive predictive value and sufficient specificity when applied within well-defined target populations. Despite these criteria, false positive diagnoses still occur and can lead to unnecessary or inappropriate treatment, as various benign and non-HCC malignant lesions may exhibit vascular features that overlap with the classic appearance of HCC. Furthermore, treatment decisions are occasionally guided by imaging findings even in patients outside the target population who are being evaluated for possible HCC, in whom vascular patterns are less specific and the risk of false positive diagnosis is inherently higher. Minimizing the risk of false positive diagnosis requires not only adherence to validated imaging criteria but also clinical and contextual integration when findings are uncertain. This includes consideration of ancillary features, tumor markers, and, when appropriate, further evaluation through biopsy, additional imaging, or follow-up. This review outlines a range of HCC mimickers and provides practical strategies to support accurate imaging interpretation and reduce false positive diagnoses in clinical practice.